CAP-1002 ( DrugBank: CAP-1002 )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 4 |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05126758 (ClinicalTrials.gov) | June 22, 2022 | 4/11/2021 | A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy | Muscular Dystrophies;Muscular Dystrophy, Duchenne;Muscular Disorders, Atrophic;Muscular Diseases;Neuromuscular Diseases;Genetic Diseases, X-Linked;Genetic Diseases, Inborn;Nervous System Diseases | Biological: CAP-1002;Drug: Placebo | Capricor Inc. | NULL | Recruiting | 10 Years | N/A | Male | 68 | Phase 3 | United States |
| 2 | NCT04428476 (ClinicalTrials.gov) | July 20, 2020 | 9/6/2020 | Open-label Extension of the HOPE-2 Trial | Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial | Duchenne Muscular Dystrophy | Biological: CAP-1002 | Capricor Inc. | NULL | Active, not recruiting | 10 Years | N/A | All | 13 | Phase 2 | United States |
| 3 | NCT03406780 (ClinicalTrials.gov) | March 4, 2018 | 15/1/2018 | A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy | Muscular Dystrophies;Muscular Dystrophy, Duchenne;Muscular Disorders, Atrophic;Muscular Diseases;Neuromuscular Diseases;Nervous System Diseases;Genetic Diseases, X-Linked;Genetic Diseases, Inborn | Biological: CAP-1002;Drug: Placebo | Capricor Inc. | NULL | Completed | 10 Years | N/A | Male | 18 | Phase 2 | United States |
| 4 | NCT02485938 (ClinicalTrials.gov) | January 2016 | 19/6/2015 | HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) | A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy;Cardiomyopathy | Drug: Allogeneic Cardiosphere-Derived Cells (CAP-1002) | Capricor Inc. | NULL | Completed | 12 Years | N/A | Male | 25 | Phase 1/Phase 2 | United States |